Foulkes C, Friedrich N, Ivan B, Stiegeler E, Magnus C, Schmidt D
PLoS Pathog. 2025; 21(1):e1012825.
PMID: 39836706
PMC: 11774494.
DOI: 10.1371/journal.ppat.1012825.
Zacharopoulou P, Lee M, Oliveira T, Thornhill J, Robinson N, Brown H
Front Immunol. 2024; 15:1352123.
PMID: 38562938
PMC: 10982389.
DOI: 10.3389/fimmu.2024.1352123.
Maliqi L, Friedrich N, Glogl M, Schmutz S, Schmidt D, Rusert P
NPJ Vaccines. 2023; 8(1):148.
PMID: 37777519
PMC: 10542815.
DOI: 10.1038/s41541-023-00746-3.
Glogl M, Friedrich N, Cerutti G, Lemmin T, Kwon Y, Gorman J
Nat Struct Mol Biol. 2023; 30(9):1323-1336.
PMID: 37605043
PMC: 10497408.
DOI: 10.1038/s41594-023-01062-z.
Kirschman J, Marin M, Chen Y, Chen J, Herschhorn A, Smith 3rd A
Viruses. 2022; 14(7).
PMID: 35891369
PMC: 9323560.
DOI: 10.3390/v14071388.
Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
Schriek A, van Haaren M, Poniman M, Dekkers G, Bentlage A, Grobben M
Front Immunol. 2022; 13:893648.
PMID: 35651621
PMC: 9150821.
DOI: 10.3389/fimmu.2022.893648.
Insights into the molecular mechanism underlying CD4-dependency and neutralization sensitivity of HIV-1: a comparative molecular dynamics study on gp120s from isolates with different phenotypes.
Li Y, Deng L, Ai S, Sang P, Yang J, Xia Y
RSC Adv. 2022; 8(26):14355-14368.
PMID: 35540760
PMC: 9079880.
DOI: 10.1039/c8ra00425k.
Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten R, Reh L, Trkola A, Morris L, Moore P
J Virol. 2021; 96(4):e0193421.
PMID: 34935437
PMC: 8865436.
DOI: 10.1128/jvi.01934-21.
Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization.
Friedrich N, Stiegeler E, Glogl M, Lemmin T, Hansen S, Kadelka C
Nat Commun. 2021; 12(1):6705.
PMID: 34795280
PMC: 8602657.
DOI: 10.1038/s41467-021-27075-0.
Domain Organization of Lentiviral and Betaretroviral Surface Envelope Glycoproteins Modeled with AlphaFold.
Hotzel I
J Virol. 2021; 96(2):e0134821.
PMID: 34705555
PMC: 8791290.
DOI: 10.1128/JVI.01348-21.
Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection.
Shipley M, Prasad V, Doepker L, Dingens A, Ralph D, Harkins E
Elife. 2021; 10.
PMID: 34263727
PMC: 8376252.
DOI: 10.7554/eLife.68110.
Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.
Zhang D, Zou S, Hu Y, Hou J, Hu X, Ren L
Front Microbiol. 2019; 10:1096.
PMID: 31178836
PMC: 6543928.
DOI: 10.3389/fmicb.2019.01096.
Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.
de Taeye S, Go E, Sliepen K, Torrents de la Pena A, Badal K, Medina-Ramirez M
J Biol Chem. 2019; 294(14):5616-5631.
PMID: 30728245
PMC: 6462529.
DOI: 10.1074/jbc.RA118.005396.
CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity.
Ivan B, Sun Z, Subbaraman H, Friedrich N, Trkola A
PLoS Biol. 2019; 17(1):e3000114.
PMID: 30650070
PMC: 6351000.
DOI: 10.1371/journal.pbio.3000114.
Effects of CD4 Binding on Conformational Dynamics, Molecular Motions, and Thermodynamics of HIV-1 gp120.
Li Y, Deng L, Yang L, Sang P, Liu S
Int J Mol Sci. 2019; 20(2).
PMID: 30634692
PMC: 6359530.
DOI: 10.3390/ijms20020260.
Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A, Balazs A
Retrovirology. 2018; 15(1):66.
PMID: 30285769
PMC: 6167872.
DOI: 10.1186/s12977-018-0449-7.
HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.
Fera D, Lee M, Wiehe K, Meyerhoff R, Piai A, Bonsignori M
Nat Commun. 2018; 9(1):1111.
PMID: 29549260
PMC: 5856820.
DOI: 10.1038/s41467-018-03565-6.
Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L, Magnus C, Kadelka C, Kuhnert D, Uhr T, Weber J
PLoS Pathog. 2018; 14(1):e1006825.
PMID: 29370298
PMC: 5806907.
DOI: 10.1371/journal.ppat.1006825.
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.
Julg B, Tartaglia L, Keele B, Wagh K, Pegu A, Sok D
Sci Transl Med. 2017; 9(406).
PMID: 28878010
PMC: 5755978.
DOI: 10.1126/scitranslmed.aal1321.
Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.
Brandenberg O, Magnus C, Rusert P, Gunthard H, Regoes R, Trkola A
PLoS Pathog. 2017; 13(5):e1006313.
PMID: 28472201
PMC: 5417720.
DOI: 10.1371/journal.ppat.1006313.